PROteolysis TArgeting Chimeras (PROTACs), as a recently identified technique in the field
of new drug development, provide new concepts for disease treatment and are expected to …

Abstract Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in
therapeutic drug development by leveraging the ubiquitin‐proteasome system to enable …

Cancer stem cells (CSCs) with hyperactivated signal transducer and activator of
transcription 3 (STAT3) are a major driver of hepatocellular carcinoma (HCC). Herein, we …

Methylation of adenine N6 (m6A) is the most frequent RNA modification. On mRNA, it is
catalyzed by the METTL3–14 heterodimer complex, which plays a key role in acute myeloid …

Proteolysis targeting chimera (PROTAC) is a state‐of‐the‐art technology for ablating
undruggable targets. A PROTAC degrader achieves targeted protein degradation (TPD) …

Sonodynamic therapy (SDT) was hampered by the sonosensitizers with low bioavailability,
tumor accumulation, and therapeutic efficiency. In situ responsive sonosensitizer self …

Microvascular dysfunction following myocardial infarction exacerbates coronary flow
obstruction and impairs the preservation of ventricular function. The apelinergic system …

Although self‐assembly has emerged as an effective tool for fabricating biomaterials,
achieving precise control over the morphologies and functionalities of the resultant …

Ovarian cancer is the deadliest gynecologic malignancy. The majority of patients diagnosed
with advanced ovarian cancer will relapse, at which point additional therapies can be …

Proteolysis targeting chimeras (PROTACs) can use the intrinsic protein degradation system
in cells to degrade pathogenic target proteins, and are currently a revolutionary frontier of …